All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with
NPM1-mutated AML unfit for intensive chemotherapy and review of the literature.
Clin Case Rep 2016;
4:1138-1146. [PMID:
27980750 PMCID:
PMC5134148 DOI:
10.1002/ccr3.723]
[Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Revised: 09/25/2016] [Accepted: 09/30/2016] [Indexed: 11/10/2022] Open
Abstract
Based upon the clinical behavior of three patients, we suggest that the combination of low‐dose Ara‐C and all‐trans retinoic acid may potentially be effective in some elderly patients, unfit for intensive chemotherapy, affected with NPM1‐mutated acute myeloid leukemia without FLT3 mutations, warranting perspective clinical studies in these selected patients.
Collapse